Navigation Links
Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
Date:3/28/2008

MONTVALE, N.J., March 28 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today reported that the Company's independent registered public accounting firm included an explanatory paragraph in their opinion on the Company's financial statements included in the recently filed Annual Report on Form 10-K for the year ended December 31, 2007, relating to the Company's ability to continue as a going concern. The Company discusses this matter, including its plans to address future financing needs, in Note 1 to the financial statements included in its Form 10-K.

This announcement is being made in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), which requires separate disclosure in a press release regarding the receipt of an auditor opinion that contains a going concern explanatory paragraph. This announcement does not represent any change or amendment to the Company's 2007 financial statements or to its Annual Report on Form 10-K.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and, schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
2. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
3. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
4. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
7. ASU researchers improve memory devices using nanotech
8. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
9. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
10. Scientists synthesize memory in yeast cells
11. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: the ... expertly narrows down the mass of product choices to ... , First, select the working environment, then enter ... and define the accuracy – it’s really that simple. ... list to models that fit best with the customer’s ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 As ... manage numerous projects in the MENA region during 2014 ... have a preferred provider agreement with DZS to manage ... MENA region,” said Global VP of R&D and President ... has developed excellent operational practices with a focus on ...
(Date:7/23/2014)... in saving China,s endangered national treasure, the giant panda. ... reserves that have been established and three large breeding ... in the wild. , Breeding programs in conservation ... improving genetic diversity, avoid inbreeding and ultimately, introduce pandas ... programs doing so far? , In a new study ...
(Date:7/23/2014)... 2014 Shimadzu Scientific Instruments has ... analysis system developed jointly with Ajinomoto Co. Inc. ... analyze 38 amino acids in nine minutes, drastically ... high-speed analysis utilizing a fast application-specific column and ... analytical results even under conditions with difficult samples ...
Breaking Biology Technology:SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2
... Abstract , ... in the biological sciences. In drug discovery research, immunoassays ... culture supernatants of treated cells. However, scientists often avoid ... cumbersome manipulations. Applied Biosystems has developed a singlestep, mix-and-read ...
... Purpose , ... of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) ... of assessing inter-individual and intra-individual metabolism variability. To be of ... to monitor these drugs is fast and easy to perform, ...
... Purpose , ... plays an important role in a number of functions, including the ... characterized by impaired, reduced or total absence of peroxisomes in cells, ... and hexacosanoic acids, in plasma. Some variants of these disorders are ...
Cached Biology Technology:Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 2Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 3Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 4Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 5A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 2A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 3A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 4A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 2A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 3A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 4
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... average over a 35 year period in which the ... of humans on declining animal numbers. This decline matters ... spiders, crustaceans, slugs and worms bring to our day-to-day ... for nutrient cycling, water filtration and human health. , ... by UCL, Stanford and UCSB, focused on the demise ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... to biobanks vast collections of human tissue samples that ... have a right to basic information about how their donations ... a new paper. The idea behind biobanks is that ... to medical records and other health information, can yield discoveries ...
... and terrorist plots are usually the preserve of Hollywood ... is the stuff of real life. As controversy about ... new paper argues for a complete overhaul of current ... Reconfiguring Global Responses to Influenza, by Dr Paul Forster, ...
... modify their body movements to be in tune with others, ... to be in synchrony with their peers. For example, we ... unison at the end of a concert. This phenomenon is ... the RIKEN Brain Science Institute report today that pairs of ...
Cached Biology News:Safeguards needed for tissue donors 2Pandemic controversies: The global response to pandemic influenza must change 2Primates too can move in unison 2
... neurons in vesicles called synaptosomes. ... bouton. Synaptosomes may be centrifuged ... cellular debris. Abnormalites in neurotransmitter release ... condtions. Conditions of release may ...
... Detection Systems allow non-radioactive detection of ... systems, biotinylated lysine residues are incorporated ... the need for labeling with [35-S]methionine ... biotinylated lysine is added to the ...
... Series Hybridization chambers with forced convection ... ambient up to 99.9 C / 212 F ... and reproducible results DS controller Timer ... with an accuracy of a tenth of a ...
... microarray data using Asuragens bioinformatics expertise. We ... to extensive data analysis using the most ... in combination with the Gene Expression Profiling ... ,Normalization and basic statistical analysis including publication ...
Biology Products: